Metrics Contract Services Enters Partnership to Develop Oncology Drug
Metrics Contract Services, the US-based contract pharmaceutical development and manufacturing division of Mayne Pharma, recently announced the signing of a development and manufacturing agreement with ESSA Pharmaceuticals. Under the terms of the agreement, Metrics will provide formulation development, analytical services and manufacturing to support the client’s ongoing clinical development of an orally administered oncology drug.
“To support this project for ESSA Pharmaceuticals, Metrics will transfer their current tablet formulation and manufacturing process into our facility, perform development work to optimize the formulation, then scale up the process to be able to manufacture clinical supplies for ESSA’s clinical needs,” said John Ross, President of Metrics Contract Services.
The project, notes Ross, will enable Metrics to demonstrate not only its longtime expertise in supporting customers with development programs and its unique ability to support commercial production from the same campus, but also its leadership in producing novel oral solid dose therapies for oncology treatment.
“We are excited to partner with ESSA on a program that is ultimately intended to benefit cancer patients. Our focus is keenly on novel drugs that make a difference.”
Metrics Contract Services is a full-service pharmaceutical development and manufacturing organization serving clients worldwide delivering proven scientific and operational excellence for novel oral dosage forms. Metrics’ areas of expertise include quality pharmaceutical formulation development; first-time-in-human formulations; Phase I-III clinical trial materials manufacturing; and analytical method development and validation services leading to commercial scale manufacturing. Technical capabilities include highly potent and unstable compounds; Schedule II-V controlled substances; and products with poor bioavailability, for which we offer an impressive portfolio of advanced delivery methods. Metrics manufactured products are now approved by medicines regulators in more than 40 countries. Located in Greenville, N.C., Metrics is a proud member of Mayne Pharma. Learn more at metricscontractservices.com.
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on the application of drug delivery expertise to commercialize branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems, and these technologies have been successfully commercialized in numerous products that continue to be marketed around the world. Mayne Pharma has two drug development and manufacturing facilities based in in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and poorly soluble compounds. For further information, visit www.maynepharma.com.
Total Page Views: 873
